VIRX insider filings
Viracta Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-11-27. Screen VIRX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for VIRX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Viracta Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-11-27 | 4 | Pomerantz Roger — Director | Option exercise (M): 9,034 @ $0 · Option exercise (M): 9,034 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | ROYSTON IVOR — Director | Option exercise (M): 25,219 @ $0 · Option exercise (M): 25,219 (derivative) @ $0 | EDGAR |
| 2024-09-12 | 4 | Pomerantz Roger — Director | Option exercise (M): 9,034 @ $0 · Option exercise (M): 9,034 (derivative) @ $0 | EDGAR |
| 2024-09-12 | 4 | ROYSTON IVOR — Director | Option exercise (M): 25,219 @ $0 · Option exercise (M): 25,219 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Borellini Flavia — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Chung Jane — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Murphy Samuel Lafayette — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | DARCY THOMAS E — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Simon Barry J. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Barlow Jane F — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Pomerantz Roger — Director | Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 18,750 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Rubino Stephen — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | ROYSTON IVOR — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | Pomerantz Roger — Director | Option exercise (M): 9,035 @ $0 · Option exercise (M): 9,035 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | ROYSTON IVOR — Director | Option exercise (M): 25,219 @ $0 · Option exercise (M): 25,219 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Faerm Michael E. — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Rothera Mark — President and CEO, Director | Grant/award (A): 475,000 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Cohen Darrel P. — Chief Medical Officer | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Chevallard Daniel R. — CFO and COO | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | Pomerantz Roger — Director | Option exercise (M): 9,034 @ $0 · Option exercise (M): 9,034 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | Chevallard Daniel R. — CFO and COO | Option exercise (M): 6,889 @ $0 · Sale (S): 3,405 @ $0.73 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | ROYSTON IVOR — Director | Option exercise (M): 25,219 @ $0 · Option exercise (M): 25,219 (derivative) @ $0 | EDGAR |
| 2023-12-04 | 4 | Rothera Mark — President and CEO, Director | Purchase (P): 52,094 @ $0.49 · Purchase (P): 47,906 @ $0.49 | EDGAR |
| 2023-11-28 | 4 | Chevallard Daniel R. — CFO and COO | Option exercise (M): 6,889 @ $0 · Sale (S): 3,720 @ $0.50 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2023-11-28 | 4 | Pomerantz Roger — Director | Option exercise (M): 9,034 @ $0 · Option exercise (M): 9,034 (derivative) @ $0 | EDGAR |
| 2023-11-28 | 4 | ROYSTON IVOR — Director | Option exercise (M): 25,219 @ $0 · Option exercise (M): 25,219 (derivative) @ $0 | EDGAR |
| 2023-08-29 | 4 | Pomerantz Roger — Director | Option exercise (M): 9,034 @ $0 · Option exercise (M): 9,034 (derivative) @ $0 | EDGAR |
| 2023-08-29 | 4 | Chevallard Daniel R. — CFO and COO | Option exercise (M): 6,888 @ $0 · Sale (S): 3,512 @ $1.45 · Option exercise (M): 6,888 (derivative) @ $0 | EDGAR |
| 2023-08-29 | 4 | ROYSTON IVOR — Director | Option exercise (M): 25,219 @ $0 · Option exercise (M): 25,219 (derivative) @ $0 | EDGAR |
| 2023-08-18 | 4 | Pomerantz Roger — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-08-18 | 4 | Cohen Darrel P. — Chief Medical Officer | Grant/award (A): 235,000 (derivative) @ $0 · Grant/award (A): 265,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Simon Barry J. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Rubino Stephen — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Pomerantz Roger — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Murphy Samuel Lafayette — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | DARCY THOMAS E — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Chung Jane — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Borellini Flavia — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Barlow Jane F — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | ROYSTON IVOR — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | Pomerantz Roger — Director | Option exercise (M): 9,035 @ $0 · Option exercise (M): 9,035 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | Chevallard Daniel R. — CFO and COO | Option exercise (M): 6,889 @ $0 · Sale (S): 3,635 @ $1.42 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2023-05-26 | 4 | ROYSTON IVOR — Director | Option exercise (M): 25,219 @ $0 · Option exercise (M): 25,219 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | Rothera Mark — President and CEO, Director | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | Rojkjaer Lisa — Chief Medical Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | Chevallard Daniel R. — CFO and COO | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Rojkjaer Lisa — Chief Medical Officer | Option exercise (M): 4,127 @ $0 · Sale (S): 2,156 @ $1.68 · Option exercise (M): 4,127 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Pomerantz Roger — Director | Option exercise (M): 9,034 @ $0 · Option exercise (M): 9,034 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | Chevallard Daniel R. — CFO and COO | Option exercise (M): 6,889 @ $0 · Sale (S): 3,599 @ $1.68 · Option exercise (M): 6,889 (derivative) @ $0 | EDGAR |
| 2023-02-28 | 4 | ROYSTON IVOR — Director | Option exercise (M): 25,219 @ $0 · Option exercise (M): 25,219 (derivative) @ $0 | EDGAR |
Recent 8-K events — Viracta Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-02-05 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-31 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-01-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-17 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-12-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-11-29 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-11-22 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-06 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VIRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs